Dymicron’s Triadyme-C artificial disc earned the FDA’s investigational device exemption approval, according to a July 10 news release.
The IDE approval opens the door for a U.S. trial of the disc, which is designed for patients with degenerative disc disease. Triadyme-C has bearing surfaces made of Adymite, a proprietary medical grade polycrystalline diamond material made for high-stress load-bearing environments.
“The Triadyme-C represents a remarkable advancement in cervical disc technology,” Richard Guyer, MD, co-primary investigator for clinical trials, said in the release. “Its revolutionary polycrystalline diamond bearing surfaces dramatically reduce wear debris generation, while the tri-lobed design is engineered to closely replicate normal spinal kinematics—two factors that could improve long-term outcomes for patients.”
The first implantations in the U.S. are expected in the fourth quarter.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
